Related Experiment Video
Updated: Jan 30, 2026

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
Designer therapies for glioblastoma multiforme
Sith Sathornsumetee1, Jeremy N Rich
1Neuro-Oncology Program, Departments of Medicine (Neurology) and Pathology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Abstract:
Primary brain tumors account for less than 2% of all cancers in adults; however, they are often associated with neurologic morbidity and high mortality. Glioblastoma multiforme (GBM) has been a focus of new therapy development in neurooncology because it is the most common primary brain tumor in adults. Standard-of-care therapy for newly diagnosed GBM includes surgical resection, radiotherapy, and temozolomide, administered both during and after radiotherapy. However, most patients develop tumor recurrence or progression after this multimodality treatment. Repeat resection and stereotactic radiosurgery upon recurrence may improve outcome only in selected patients. Most salvage chemotherapies offer only palliation. Recent advances in our understanding of the molecular abnormalities of GBM have generated new therapeutic venues of molecularly targeted agents (designer drugs) against key components of cellular pathways critical for cancer initiation and maintenance. Such drugs may offer the potential advantage to increase therapeutic efficacy and decrease systemic toxicity compared with traditional cytotoxic agents. Nonetheless, first-generation targeted agents have failed to demonstrate survival benefits in unselected GBM patient populations. Several mechanisms of treatment failure of the first-generation designer drugs have been proposed, whereas new strategies have been developed to increase effectiveness of these agents. Here we will discuss the recent development and the strategies to optimize the effectiveness of designer therapy for GBM.
Insights
Glioblastoma multiforme (GBM) is a deadly brain cancer. While standard treatments exist, recurrence is common. New molecularly targeted therapies show promise for improving GBM treatment outcomes.
Area of Science:
- Neuro-oncology
- Cancer Biology
- Molecular Therapeutics
Background:
- Primary brain tumors are rare but aggressive, with Glioblastoma multiforme (GBM) being the most common and lethal adult form.
- Current standard-of-care for GBM (surgery, radiation, temozolomide) often leads to tumor recurrence.
- Salvage therapies for recurrent GBM provide limited benefits, necessitating novel treatment approaches.
Purpose of the Study:
- To review recent advancements in molecularly targeted agents for GBM.
- To discuss strategies for optimizing the effectiveness of these novel designer drugs.
- To explore new therapeutic avenues beyond traditional cytotoxic chemotherapy for GBM.
Main Methods:
- Review of current literature on GBM molecular abnormalities and targeted therapies.
- Analysis of proposed mechanisms for the failure of first-generation targeted agents.
- Discussion of emerging strategies to enhance the efficacy of molecularly targeted drugs in GBM.
Main Results:
- Understanding GBM molecular pathways has identified new targets for designer drugs.
- First-generation targeted agents have not yet shown survival benefits in unselected GBM populations.
- New strategies are being developed to overcome treatment resistance and improve targeted therapy effectiveness.
Conclusions:
- Molecularly targeted agents offer potential for increased efficacy and reduced toxicity in GBM treatment.
- Overcoming treatment failure mechanisms is crucial for successful implementation of designer drugs.
- Optimizing targeted therapy strategies is essential for improving outcomes in patients with Glioblastoma multiforme.
More Related Videos
Related Concept Videos
Design Example: Design of an Irrigation Channel
Group Design
Gene Therapy
Factorial Design
Design Example: Designing a Residential Plumbing System
Design Example: Designing Water Slide
Bernoulli's principle determines the water's velocity along the slide....

